Myriad Genetics
MYGN
196 hedge funds and large institutions have $828M invested in Myriad Genetics in 2020 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 74 increasing their positions, 57 reducing their positions, and 22 closing their positions.
36% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 22
30% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 57
25% more call options, than puts
Call options by funds: $3.12M | Put options by funds: $2.5M
3% more funds holding
Funds holding: 190 → 196 (+6)
1% less ownership
Funds ownership: 98.96% → 97.95% (-1%)
22% less capital invested
Capital invested by funds: $1.06B → $828M (-$228M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$23.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$18.2M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$12M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$12M |
| 5 |
Two Sigma Investments
New York
|
+$9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$128M |
| 2 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
-$11.9M |
| 3 |
Mitsubishi UFJ Trust & Banking
Tokyo,
Japan
|
-$6.24M |
| 4 |
Morgan Stanley
New York
|
-$3.92M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.03M |
MYGN Hedge Fund Activity: Q2 2020 in Review
196 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q2 2020, worth a combined $828M — down 22% from $1.06B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new MYGN positions and 22 closed out — a net gain of 8 holders — while 74 added to existing stakes and 57 trimmed.
The largest buyer was Camber Capital Management, adding an estimated $23.4M. The largest seller was Baillie Gifford & Co, exiting entirely with an estimated $128M sold.
- 196 institutional investors held Myriad Genetics (MYGN) as of Q2 2020, up from 190 in Q1 2020.
- Funds reported $828M of Myriad Genetics stock for Q2 2020, down 22% quarter-over-quarter.
- 30 funds opened new Myriad Genetics positions in Q2 2020 and 22 closed out, a net change of +8 holders.
- The largest Myriad Genetics buyer in Q2 2020 was Camber Capital Management, an estimated $23.4M added.
- The largest Myriad Genetics seller in Q2 2020 was Baillie Gifford & Co, an estimated $128M sold.
Based on aggregated 13F filings for Q2 2020.